首頁 > 市場調查報告書 > 製藥

非專利藥

市場調查報告書

商品編碼

1565599

學名藥的全球市場:類型·品牌·適應症·給藥途徑·通路·不同地區的預測 (～2032年)

Global Generic Drugs Market Research Report Information by Type, by Brand, by Indication, by Route of Administration, by Distribution Channel, and by Region - Forecast till 2032

出版日期: 2024年08月10日 | 出版商:

Market Research Future | 英文 160 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球仿製藥市場規模將從2023年的4106億美元增長到2024年的4379億美元，預測期內複合年增長率為7.85%，預計到2032年將增長到8743.6億美元。

全球慢性病盛行率上升以及進入者策略活動的增加正在推動全球仿製藥產業的發展。儘管進入者自願召回產品可能會限制市場成長，但對仿製藥研發的投資仍將創造有吸引力的市場前景。

全球慢性病的增加是全球仿製藥市場成長的主要驅動力。隨著癌症、神經系統疾病、心血管疾病和發炎性疾病的治療方法不斷增加，對低成本治療選擇的需求正在推動患者和醫療保健提供者轉向仿製藥。

區域洞察

由於醫院和醫療機構對仿製藥的需求增加、技術進步以及慢性病患病率上升等原因，北美仿製藥市場正在迅速擴大。

由於其完善的醫療保健基礎設施以及促進參與企業、研究機構和醫療保健提供者之間的合作和聯盟，歐洲的仿製藥市場佔有第二大佔有率。

預計2023年至2032年亞太地區仿製藥市場成長最快。這是由於癌症、糖尿病和心血管疾病等慢性病的流行、醫療保健支出的增加以及研發投資的增加。

本報告提供全球學名藥的市場調查，彙整市場定義和概要，市場成長的各種影響因素分析，市場規模的轉變·預測，各種區分·各地區的明細，競爭環境，主要企業簡介等資訊。

Global Generic Drugs Market Research Report Information by Type (Simple Generics and Super Generics), by Brand (Pure Generic and Branded Generic), by Indication (Central Nervous System (CNS), Cardiovascular, Urology, Oncology, Respiratory, and Others), by Route of Administration (Oral, Topical, Parenteral, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Europe, Asia-Pacific, and Rest of the World - Forecast till 2032

Market Overview

In 2023, the generic drugs market was valued at USD 410.60 billion. The Generic Drugs Market is expected to increase from USD 437.90 billion in 2024 to USD 874.36 billion by 2032, with a compound annual growth rate (CAGR) of 7.85% over the forecast period (2024-2032). The worldwide generic medicine industry is being driven by rising prevalence of chronic diseases around the world, as well as increased strategic activities by market players. However, voluntary product recalls by industry participants are projected to impede global market growth. Nonetheless, investment in research and development (R&D) for generic pharmaceuticals is expected to generate attractive market prospects.

The rising prevalence of chronic diseases around the world is a primary driver of the global generic medication market's growth. With ailments including cancer, neurology, cardiovascular diseases, inflammatory diseases, and others on the rise, there is an increased desire for low-cost treatment choices, prompting patients and healthcare providers to turn to generic pharmaceuticals.

Market Segment insights

The Generic Drugs Market is segmented by kind, with simple generics and super generics.

The Generic Drugs Market is segmented by brand into pure generic and branded generic.

The Generic Drugs Market is segmented by indication, including central nervous system (CNS), cardiovascular, urology, cancer, respiratory, and others.

Regional insights

The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American Generic Drugs market is expanding rapidly, driven by reasons such as increased demand for Generic Drugs in hospitals and medical settings, technological improvements, and the rising prevalence of chronic conditions.

The Europe Generic Drugs market accounted for the second-largest market share due to well-established healthcare infrastructure, which is driven by collaborations and partnerships between industry players, research organizations, and healthcare providers. Furthermore, Germany Generic Drugs providers are said to have the greatest market share, while France Generic Drugs providers are expected to be the fastest rising market in Europe.

The Asia-Pacific Generic Drugs market is predicted to expand the fastest from 2023 to 2032, owing to the prevalence of chronic medical problems such as cancer, diabetes, and cardiovascular disease, as well as increased healthcare spending and investments in R&D. Furthermore, China Generic Drugs accounted for the greatest market share, while India Generic Drugs is expected to be the fastest expanding market in the Asia Pacific region.

Major Players

Sun Pharmaceutical Industries Ltd. (India), Lupin Pharmaceuticals, Inc. (India), Endo International plc (Ireland), Aurobindo Pharma (India), Aspen Holdings (South Africa), Teva Pharmaceuticals Industries Ltd. (Israel), Viatris Inc. (US), Cipla ltd. (India), Fresenius SE & Co. KGaA (Germany), and Novartis AG (Switzerland) are among the key companies in the Generic Drugs market.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES ACROSS THE GLOBE
- 4.2.2 RISING STRATEGIC INITIATIVES BY MARKET PLAYERS
4.3 RESTRAINTS
- 4.3.1 VOLUNTARY PRODUCT RECALLS FROM MARKET PLAYERS
4.4 OPPORTUNITY
- 4.4.1 INVESMTENT ON RESEARCH & DEVELOPMENT (R&D) FOR GENERIC MEDICINE

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL GENERIC DRUGS MARKET
5.3 TRENDS IN DEVELOPMENTS OF INDIVIDUAL MARKETS (EU, USA, INDIA, CHINA, OTHER)
5.4 TRENDS IN THE DEVELOPMENT OF THERAPEUTIC AREAS
5.5 TRENDS IN MANUFACTURING SITES
5.6 TRENDS IN NEW TECHNOLOGICAL PLATFORMS FOR DRUGS
5.7 TRENDS IN IP
5.8 TRENDS IN QUALITY REQUIREMENTS
5.9 TRENDS IN REGULATORY REQUIREMENTS

6 GLOBAL GENERIC DRUGS MARKET, BY TYPE

6.1 OVERVIEW
6.2 SIMPLE GENERICS
6.3 SUPER GENERICS

7 GLOBAL GENERIC DRUGS MARKET, BY BRAND

7.1 OVERVIEW
7.2 PURE GENERIC
7.3 BRANDED GENERIC

8 GLOBAL GENERIC DRUGS MARKET, BY INDICATION

8.1 OVERVIEW
8.2 CENTRAL NERVOUS SYSTEM (CNS)
8.3 CARDIOVASCULAR
8.4 UROLOGY
8.5 ONCOLOGY
8.6 RESPIRATORY
8.7 OTHERS

9 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION

9.1 OVERVIEW
9.2 ORAL
9.3 TOPICAL
9.4 PARENTERAL
9.5 OTHERS

10 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW
10.2 HOSPITAL PHARMACY
10.3 RETAIL PHARMACY
10.4 ONLINE PHARMACY

11 GLOBAL GENERIC DRUGS MARKET, BY REGION

11.1 OVERVIEW
11.2 NORTH AMERICA
- 11.2.1 US
- 11.2.2 CANADA
11.3 EUROPE
- 11.3.1 GERMANY
- 11.3.2 FRANCE
- 11.3.3 UK
- 11.3.4 ITALY
- 11.3.5 SPAIN
- 11.3.6 REST OF EUROPE
11.4 ASIA-PACIFIC
- 11.4.1 CHINA
- 11.4.2 INDIA
- 11.4.3 JAPAN
- 11.4.4 SOUTH KOREA
- 11.4.5 AUSTRALIA
- 11.4.6 REST OF ASIA-PACIFIC
11.5 REST OF THE WORLD
- 11.5.1 MIDDLE EAST & AFRICA
- 11.5.2 LATIN AMERICA

12 COMPETITIVE LANDSCAPE

12.1 INTRODUCTION
12.2 MARKET SHARE ANALYSIS,
12.3 COMPETITOR DASHBOARD
12.4 PUBLIC PLAYERS STOCK SUMMARY
12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 12.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL
- 12.6.2 EXPANSION

13 COMPANY PROFILES

13.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
- 13.1.1 COMPANY OVERVIEW
- 13.1.2 FINANCIAL OVERVIEW
- 13.1.3 PRODUCTS OFFERED
- 13.1.4 KEY DEVELOPMENTS
- 13.1.5 SWOT ANALYSIS
- 13.1.6 KEY STRATEGIES
13.2 LUPIN PHARMACEUTICALS, INC.
- 13.2.1 COMPANY OVERVIEW
- 13.2.2 FINANCIAL OVERVIEW
- 13.2.3 PRODUCTS OFFERED
- 13.2.4 KEY DEVELOPMENTS
- 13.2.5 SWOT ANALYSIS
- 13.2.6 KEY STRATEGIES
13.3 ENDO INTERNATIONAL PLC
- 13.3.1 COMPANY OVERVIEW
- 13.3.2 FINANCIAL OVERVIEW
- 13.3.3 PRODUCTS OFFERED
- 13.3.4 KEY DEVELOPMENTS
- 13.3.5 KEY STRATEGIES
13.4 AUROBINDO PHARMA
- 13.4.1 COMPANY OVERVIEW
- 13.4.2 FINANCIAL OVERVIEW
- 13.4.3 PRODUCTS OFFERED
- 13.4.4 KEY DEVELOPMENTS
- 13.4.5 KEY STRATEGIES
13.5 ASPEN HOLDINGS
- 13.5.1 COMPANY OVERVIEW
- 13.5.2 FINANCIAL OVERVIEW
- 13.5.3 PRODUCTS OFFERED
- 13.5.4 KEY DEVELOPMENTS
- 13.5.5 KEY STRATEGIES
13.6 CIPLA LTD
- 13.6.1 COMPANY OVERVIEW
- 13.6.2 FINANCIAL OVERVIEW
- 13.6.3 PRODUCTS OFFERED
- 13.6.4 KEY DEVELOPMENTS
- 13.6.5 SWOT ANALYSIS
- 13.6.6 KEY STRATEGIES
13.7 NOVARTIS AG
- 13.7.1 COMPANY OVERVIEW
- 13.7.2 FINANCIAL OVERVIEW
- 13.7.3 PRODUCTS OFFERED
- 13.7.4 KEY DEVELOPMENTS
- 13.7.5 SWOT ANALYSIS
- 13.7.6 KEY STRATEGIES
13.8 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 13.8.1 COMPANY OVERVIEW
- 13.8.2 FINANCIAL OVERVIEW
- 13.8.3 PRODUCTS OFFERED
- 13.8.4 KEY DEVELOPMENTS
- 13.8.5 SWOT ANALYSIS
- 13.8.6 KEY STRATEGIES
13.9 FRESENIUS SE & CO. KGAA
- 13.9.1 COMPANY OVERVIEW
- 13.9.2 FINANCIAL OVERVIEW
- 13.9.3 PRODUCTS OFFERED
- 13.9.4 KEY DEVELOPMENTS
- 13.9.5 KEY STRATEGIES
13.10 VIATRIS INC.
- 13.10.1 COMPANY OVERVIEW
- 13.10.2 FINANCIAL OVERVIEW
- 13.10.3 PRODUCTS OFFERED
- 13.10.4 KEY DEVELOPMENTS
- 13.10.5 KEY STRATEGIES

簡介目錄圖表

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 TRENDS IN REGULATORY REQUIREMENTS
TABLE 3 GLOBAL GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL GENERIC DRUGS MARKET, FOR SIMPLE GENERICS, BY REGION, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL GENERIC DRUGS MARKET, FOR SUPER GENERICS, BY REGION, 2019-2032 (USD BILLION)
TABLE 6 GLOBAL GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 7 GLOBAL GENERIC DRUGS MARKET, FOR PURE GENERIC, BY REGION, 2019-2032 (USD BILLION)
TABLE 8 GLOBAL GENERIC DRUGS MARKET, FOR BRANDED GENERIC, BY REGION, 2019-2032 (USD BILLION)
TABLE 9 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 10 GLOBAL GENERIC DRUGS MARKET, FOR CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2019-2032 (USD BILLION)
TABLE 11 GLOBAL GENERIC DRUGS MARKET, FOR CARDIOVASCULAR, BY REGION, 2019-2032 (USD BILLION)
TABLE 12 GLOBAL GENERIC DRUGS MARKET, FOR UROLOGY, BY REGION, 2019-2032 (USD BILLION)
TABLE 13 GLOBAL GENERIC DRUGS MARKET, FOR ONCOLOGY, BY REGION, 2019-2032 (USD BILLION)
TABLE 14 GLOBAL GENERIC DRUGS MARKET, FOR RESPIRATORY, BY REGION, 2019-2032 (USD BILLION)
TABLE 15 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD BILLION)
TABLE 16 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 17 GLOBAL GENERIC DRUGS MARKET, FOR ORAL, BY REGION, 2019-2032 (USD BILLION)
TABLE 18 GLOBAL GENERIC DRUGS MARKET, FOR TOPICAL, BY REGION, 2019-2032 (USD BILLION)
TABLE 19 GLOBAL GENERIC DRUGS MARKET, FOR PARENTERAL, BY REGION, 2019-2032 (USD BILLION)
TABLE 20 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD BILLION)
TABLE 21 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 22 GLOBAL GENERIC DRUGS MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2019-2032 (USD BILLION)
TABLE 23 GLOBAL GENERIC DRUGS MARKET, FOR RETAIL PHARMACY, BY REGION, 2019-2032 (USD BILLION)
TABLE 24 GLOBAL GENERIC DRUGS MARKET, FOR ONLINE PHARMACY, BY REGION, 2019-2032 (USD BILLION)
TABLE 25 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2019-2032 (USD BILLION)
TABLE 26 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 27 NORTH AMERICA: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 28 NORTH AMERICA: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 29 NORTH AMERICA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 30 NORTH AMERICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 31 NORTH AMERICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 32 US: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 33 US: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 34 US: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 35 US: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 36 US: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 37 CANADA: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 38 CANADA: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 39 CANADA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 40 CANADA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 41 CANADA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 42 EUROPE: GENERIC DRUGS MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 43 EUROPE: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 44 EUROPE: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 45 EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 46 EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 47 EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 48 GERMANY: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 49 GERMANY: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 50 GERMANY: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 51 GERMANY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 52 GERMANY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 53 FRANCE: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 54 FRANCE: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 55 FRANCE: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 56 FRANCE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 57 FRANCE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 58 UK: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 59 UK: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 60 UK: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 61 UK: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 62 UK: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 63 ITALY: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 64 ITALY: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 65 ITALY: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 66 ITALY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 67 ITALY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 68 SPAIN: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 69 SPAIN: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 70 SPAIN: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 71 SPAIN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 72 SPAIN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 73 REST OF EUROPE: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 74 REST OF EUROPE: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 75 REST OF EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 76 REST OF EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 77 REST OF EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 78 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 79 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 80 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 81 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 82 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 83 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 84 CHINA: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 85 CHINA: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 86 CHINA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 87 CHINA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 88 CHINA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 89 INDIA: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 90 INDIA: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 91 INDIA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 92 INDIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 93 INDIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 94 JAPAN: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 95 JAPAN: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 96 JAPAN: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 97 JAPAN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 98 JAPAN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 99 SOUTH KOREA: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 100 SOUTH KOREA: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 101 SOUTH KOREA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 102 SOUTH KOREA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 103 SOUTH KOREA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 104 AUSTRALIA: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 105 AUSTRALIA: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 106 AUSTRALIA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 107 AUSTRALIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 108 AUSTRALIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 109 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 110 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 111 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 112 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 113 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 114 REST OT THE WORLD: GENERIC DRUGS MARKET, BY REGION, 2019-2032 (USD BILLION)
TABLE 115 REST OF THE WORLD: GENERIC DRUGS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
TABLE 116 REST OF THE WORLD: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 117 REST OF THE WORLD: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 118 REST OF THE WORLD: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 119 REST OF THE WORLD: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 120 MIDDLE EAST & AFRICA: GENERIC DRUGS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
TABLE 121 MIDDLE EAST & AFRICA: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 122 MIDDLE EAST & AFRICA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 123 MIDDLE EAST & AFRICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 124 MIDDLE EAST & AFRICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 125 LATIN AMERICA: GENERIC DRUGS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
TABLE 126 LATIN AMERICA: GENERIC DRUGS MARKET, BY BRAND, 2019-2032 (USD BILLION)
TABLE 127 LATIN AMERICA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 128 LATIN AMERICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 129 LATIN AMERICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 130 PUBLIC PLAYERS STOCK SUMMARY
TABLE 131 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 132 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 133 EXPANSION
TABLE 134 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT OFFERED
TABLE 135 SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS
TABLE 136 LUPIN PHARMACEUTICALS, INC.: PRODUCT OFFERED
TABLE 137 LUPIN PHARMACEUTICALS, INC.: KEY DEVELOPMENTS
TABLE 138 ENDO INTERNATIONAL PLC: PRODUCT OFFERED
TABLE 139 ENDO INTERNATIONAL PLC: KEY DEVELOPMENTS
TABLE 140 AUROBINDO PHARMA: PRODUCT OFFERED
TABLE 141 AUROBINDO PHARMA: KEY DEVELOPMENTS
TABLE 142 ASPEN HOLDINGS: PRODUCT OFFERED
TABLE 143 CIPLA LTD.: PRODUCTS OFFERED
TABLE 144 CIPLA LTD.: KEY DEVELOPMENTS
TABLE 145 NOVARTIS AG: PRODUCTS OFFERED
TABLE 146 NOVARTIS AG: KEY DEVELOPMENTS
TABLE 147 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERED
TABLE 148 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS
TABLE 149 FRESENIUS SE & CO. KGAA: PRODUCT OFFERED
TABLE 150 FRESENIUS SE & CO. KGAA: KEY DEVELOPMENTS
TABLE 151 VIATRIS INC.: PRODUCT OFFERED
TABLE 152 VIATRIS INC.: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 GLOBAL GENERIC DRUGS MARKET: STRUCTURE
FIGURE 2 GLOBAL GENERIC DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL GENERIC DRUGS MARKET
FIGURE 6 GLOBAL GENERIC DRUGS MARKET, TYPE SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)
FIGURE 7 GLOBAL GENERIC DRUGS MARKET, BY TYPE, 2022 & 2032 (USD BILLION)
FIGURE 8 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY TYPE,
FIGURE 9 GLOBAL GENERIC DRUGS MARKET, BRAND SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)
FIGURE 10 GLOBAL GENERIC DRUGS MARKET, BY BRAND, 2022 & 2032 (USD BILLION)
FIGURE 11 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY BRAND,
FIGURE 12 GLOBAL GENERIC DRUGS MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)
FIGURE 13 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2022 & 2032 (USD BILLION)
FIGURE 14 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY INDICATION,
FIGURE 15 GLOBAL GENERIC DRUGS MARKET, ROUTE OF ADMINISTRATION SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)
FIGURE 16 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022 & 2032 (USD BILLION)
FIGURE 17 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION,
FIGURE 18 GLOBAL GENERIC DRUGS MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)
FIGURE 19 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022 & 2032 (USD BILLION)
FIGURE 20 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL,
FIGURE 21 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2022 & 2032 (USD BILLION)
FIGURE 22 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY REGION,
FIGURE 23 NORTH AMEICA MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2032 (USD BILLION)
FIGURE 24 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)
FIGURE 25 NORTH AMERICA: GENERIC DRUGS MARKET SHARE (%), BY COUNTRY,
FIGURE 26 EUROPE MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2032 (USD BILLION)
FIGURE 27 EUROPE: GENERIC DRUGS MARKET, BY REGION, 2022 & 2032 (USD BILLION)
FIGURE 28 EUROPE: GENERIC DRUGS MARKET SHARE (%), BY REGION,
FIGURE 29 ASIA-PACIFIC MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2032 (USD BILLION)
FIGURE 30 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)
FIGURE 31 ASIA-PACIFIC: GENERIC DRUGS MARKET SHARE (%), BY COUNTRY,
FIGURE 32 REST OF THE WORLD MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2032 (USD BILLION)
FIGURE 33 REST OT THE WORLD: GENERIC DRUGS MARKET, BY REGION, 2022 & 2032 (USD BILLION)
FIGURE 34 REST OT THE WORLD: GENERIC DRUGS MARKET SHARE (%), BY REGION,
FIGURE 35 GENERIC DRUGS MARKET PLAYERS: COMPETITIVE ANALSIS,
FIGURE 36 COMPETITOR DASHBOARD: GLOBAL GENERIC DRUGS MARKET
FIGURE 37 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 39 LUPIN PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 LUPIN PHARMACEUTICALS, INC.: SWOT ANALYSIS
FIGURE 41 ENDO INTERNATIONAL PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 42 AUROBINDO PHARMA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 43 ASPEN HOLDINGS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 44 CIPLA LTD.: FINANCIAL OVERVIEW
FIGURE 45 CIPLA LTD.: SWOT ANALYSIS
FIGURE 46 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 47 NOVARTIS AG: SWOT ANALYSIS
FIGURE 48 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 49 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 50 FRESENIUS SE & CO. KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 51 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT